Overcoming Endocrine Resistance in Metastatic Breast Cancer: A Randomized Trial With Factorial Design Comparing Fulvestrant +/- Lapatinib +/- Aromatase Inhibitor [exemestane, anastrozole, letrozole] in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy

Trial Profile

Overcoming Endocrine Resistance in Metastatic Breast Cancer: A Randomized Trial With Factorial Design Comparing Fulvestrant +/- Lapatinib +/- Aromatase Inhibitor [exemestane, anastrozole, letrozole] in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lapatinib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms OVER
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top